These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20067811)

  • 1. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome.
    Negussie AH; Miller JL; Reddy G; Drake SK; Wood BJ; Dreher MR
    J Control Release; 2010 Apr; 143(2):265-73. PubMed ID: 20067811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NGR peptide ligands for targeting CD13/APN identified through peptide array screening resemble fibronectin sequences.
    Soudy R; Ahmed S; Kaur K
    ACS Comb Sci; 2012 Nov; 14(11):590-9. PubMed ID: 23030271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-labeled cyclic NGR peptide for microPET imaging of CD13 receptor expression.
    Shao Y; Liang W; Kang F; Yang W; Ma X; Li G; Zong S; Chen K; Wang J
    Molecules; 2014 Aug; 19(8):11600-12. PubMed ID: 25100253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.
    Curnis F; Cattaneo A; Longhi R; Sacchi A; Gasparri AM; Pastorino F; Di Matteo P; Traversari C; Bachi A; Ponzoni M; Rizzardi GP; Corti A
    J Biol Chem; 2010 Mar; 285(12):9114-23. PubMed ID: 20064928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Performance Evaluation of
    Képes Z; Arató V; Szabó JP; Gyuricza B; Szücs D; Hajdu I; Fekete A; Bruchertseifer F; Szikra D; Trencsényi G
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
    Chen Y; Wu JJ; Huang L
    Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NGR-peptide-drug conjugates with dual targeting properties.
    Enyedi KN; Tóth S; Szakács G; Mező G
    PLoS One; 2017; 12(6):e0178632. PubMed ID: 28575020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Class of Ultrasound-Triggerable Drug Delivery Systems for the Improved Treatment of Tumors.
    Zhou C; Xie X; Yang H; Zhang S; Li Y; Kuang C; Fu S; Cui L; Liang M; Gao C; Yang Y; Gao C; Yang C
    Mol Pharm; 2019 Jul; 16(7):2956-2965. PubMed ID: 31084010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
    J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NGR Tumor-Homing Peptides: Structural Requirements for Effective APN (CD13) Targeting.
    Graziadio A; Zanda M; Frau S; Fleming IN; Musolino M; Dall'Angelo S; Baldassarre M; Piras M
    Bioconjug Chem; 2016 May; 27(5):1332-40. PubMed ID: 27077642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
    Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
    Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of
    Yang Y; Zhang J; Zou H; Shen Y; Deng S; Wu Y
    J Cancer; 2021; 12(1):244-252. PubMed ID: 33391421
    [No Abstract]   [Full Text] [Related]  

  • 15. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of
    Zhao M; Yang W; Zhang M; Li G; Wang S; Wang Z; Ma X; Kang F; Wang J
    Tumour Biol; 2016 Sep; 37(9):12123-12131. PubMed ID: 27220318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
    Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroPET imaging of CD13 expression using a (64)Cu-labeled dimeric NGR peptide based on sarcophagine cage.
    Li G; Wang X; Zong S; Wang J; Conti PS; Chen K
    Mol Pharm; 2014 Nov; 11(11):3938-46. PubMed ID: 25054774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
    Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
    Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A photo-responsive peptide- and asparagine-glycine-arginine (NGR) peptide-mediated liposomal delivery system.
    Xie X; Yang Y; Yang Y; Zhang H; Li Y; Mei X
    Drug Deliv; 2016 Sep; 23(7):2445-2456. PubMed ID: 25693640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.